Tag Archives: innovation

University Relations

Robert Coridan, assistant professor of chemistry and biochemistry in the Fulbright College of Arts and Sciences.

Robert Coridan, assistant professor of chemistry and biochemistry, recently received two individual awards totaling $110,000 at the Scialog: Negative Emissions Science conference, a meeting of Scialog Fellows sponsored by the Research Corporation for Scientific Advancement and the Sloan Foundation. Coridan is a principal investigator on two projects honored by Scialog, "Using Electrochemistry to Improve Selectivity of Plasma-Assisted CO2 Reduction" and "Integrated Low-Temperature Electrified Process for CO2 Direct Air Capture and Transformation to Solid Carbon."

The 2020 Scialog Collaborative Innovation Awards were given to eight collaborative research teams, representing universities across the United States and Canada. Coridan is working with researchers from the University of British Columbia, the University of California, Irvine, the University of Rochester and the University of California, Los Angeles.

A Scialog (a combination of the words "science" and "dialog") is meant to help develop a research community to address scientific challenges of global significance. Scialog Fellows participate in annual meetings over the three-year course of the Scialog to develop collaborations and ideas to tackle these challenges. The Collaborative Innovation Awards initiate research into ideas developed at the meetings. The 2020 Scialog for Negative Emissions Science, held virtually in November, was the first to address solutions for the removal and utilization of greenhouse gases. Other Scialogs have considered topics from a broad range of scientific disciplines, including Advanced Energy Storage, the Chemical Machinery of the Cell, and Signatures of Life in the Universe. Funding for the research awards was provided by the Research Corporation for Science Advancement, the Alfred P. Sloan Foundation and the Thistledown Foundation.

Neuroscience

$25 million donation to fund brain science research at Brown – The Brown Daily Herald

February 9, 2021 medical

A $25 million gift from an anonymous donor will support new, innovative research projects in the field of brain science at the University. The donation will also fund the Innovation Awards Program at the Robert J. and Nancy D. Carney Institute for Brain Science.

Research, discovery and innovation is a long-term process, Diane Lipscombe, director of the Carney Institute for Brain Science and professor in neuroscience, said. Gifts like this stimulate the leading edge of a field where we have phenomenal researchers already. It will season the existing momentum.

Although the distribution of the gift is still being discussed, a portion of the funds will be devoted to computational brain science research. A lot of progress has been made regarding the computational functions of the nervous center, especially the brain, but we are only scratching the surface, Director of the Carney Center for Computational Science Michael Frank said.

Computational brain science research has the potential to expand across different fields, according to Frank. In his own research lab, Frank applies machine learning to study psychiatry and neurology through a computational approach, which can help inform the development of pharmaceuticals and other therapies for mental health.

Another way this gift can impact promising research is through the Innovation Awards Program, which invests in early research projects. One key element to stimulate innovation is by putting some resources into ideas at the point of inception, Lipscombe said.

The National Institutes of Health is typically more conservative, funding less risky, long-term projects with more data, Lipscombe said. We want to fill in the gap between the point of establishing creative ideas and receiving stable funding.

University Professor of Brain Science Alexander Jaworski, a recipient of an Innovation Award in 2015-16, has identified the molecules that determine the assembly of neurons with his lab. Through this research, the researchers discerned the evolutionary history of such molecules.

Discoveries like Jaworskis have applications across multiple disciplines. From a human health perspective, our work can help understand the etiology of neurodevelopmental disorders, and it can inform therapeutic approaches to repair networks of neurons in the brain, Jaworski wrote in an email to The Herald.

Jaworski currently aims to use computational methods to uncover how dynamic changes in gene expression impact neural function. This work will benefit from the expansion of resources, computational infrastructure and faculty collaboration in the brain science field, according to Jaworski.

A gift of this size is obviously a huge vote of confidence for brain science at Brown, Jaworski wrote. It can serve as a great recruiting tool and elevate computational neuroscience at Brown to the next level.

Read this article:
$25 million donation to fund brain science research at Brown - The Brown Daily Herald

Genetics

Front Range Biosciences Introduces A New Class of THCv Genetics That Will Boost Market Opportunities for New Consumer Experiences and Functional…

February 9, 2021 medical

BOULDER, Colo., Feb. 9, 2021 /PRNewswire/ -- Front Range Biosciences ("FRB"), a cannabis and hemp genetics platform company, leveraging next generation breeding technology and R&D, todaybecame one of the first genetics providers to launch a new product line of high THCv plant varieties, in California, with availability in Colorado through licensed partners leveraging FRB's technology platform. This first generation product line is among the highest producers of THCv available, containing more than 20% total cannabinoids, more than 8% THCv, and over 2% grassy and fruity terpenes. These new varieties yield twice the yield of typical THCv producing plants. THCv is rare and has been an elusive minor cannabinoid until now, with exciting new properties for consumers that report appetite suppression and energizing, less psychoactive experiences.

"FRB is continually developing new genetics to help growers, brands, and consumers find new applications for cannabis," said Dr. Jonathan Vaught, CEO of Front Range Biosciences. "The cannabis market is evolving quickly, and consumers are constantly looking for new and unique experiences, just like in other CPG industries. We are leveraging genomics driven breeding to rapidly develop new products for cannabis companies and brands, unlocking new product opportunities from the incredible diversity of chemistry this plant produces. THCv represents just one of many new products we are making more accessible to the supply chain from this versatile plant through breeding, and we have many other unique products in development for other potential categories like edible ingredients, nutraceuticals and even pharmaceuticals.

This is the first THCv product line from FRB's world-renowned breeding program and expansive cannabis genetics library. This revolutionary THCv variety will pave the way for more unique consumer products, medical research and therapeutics. There is also a growing body of research linking THCv to a number of potential therapeutic benefits, including regulating tremors and seizures in ALS and Parkinson's patients, blocking fight or flight responses in PTSD, and acting as an effective analgesic for treating pain and migraines.

Since FRB's strain debuted on the market in California, it has become a favorite among local consumers. "It has a smooth, spicy-sweet smoke that creates a functional high. The THCv allows me to stay focused throughout the day, and I love that it's the opposite of most cannabis flower and keeps the munchies at bay," said Tricia Goldberg.

FRB's latest offering makes THCv more accessible by providing genetics that drastically increase yields, significantly reduce harvest times, deliver a variety of terpenes for improved flavor, as well as produce significantly higher levels of THCv, compared to the limited number of other THCv genetics that are currently available. These improvements in the finished product profile will open the door for new product opportunities for THCv flower-based products including smokable flower, pre-rolls, and concentrates, providing exciting new experiences for cannabis consumers.

"THCv, along with other minor cannabinoids, terpenes, and even flavonoids, have been a challenging group of traits for breeders to develop while maintaining the level of vigor and yield needed to introduce these products into the supply chain effectively," says Dr. Reggie Gaudino, VP of R&D for Front Range Biosciences. "The many years of genomics and chemistry research our team has been committed to for cannabis is allowing us to help growers and product companies do so much more with the plant than what was possible, even just a few years ago."

Growers have faced challenges producing cannabis containing high THCv content. The price of THCv has remained high due to significant lack of supply, and product availability has been extremely limited. This new class of THCv genetic products provides a timely solution to both issues, creating lucrative opportunities for cultivators and operators.

About Front Range Biosciences Front Range Biosciences is a premier cannabis and hemp genetics platform company, creating and supporting innovative new products across multiple industries by combining next generation agricultural technologies with the world's top hemp and cannabis R&D program. FRB provides leading-edge solutions to growers, brands, and product manufacturers through its unique varieties of seeds, young plants, and technology licensing to drive product development and production efficiency for cannabis and hemp derived products. Since 2015, the company has been dedicated to creating new product opportunities and solving challenges throughout the supply chain by leveraging proprietary next generation breeding, chemistry, and tissue culture technologies. In addition to FRB's groundbreaking technology, the company has also established genetics services dedicated to the California market and a Shimadzu sponsored Hemp Center of Excellence with top-tier researchers to encourage further innovation in the industry. FRB is the company of choice for cultivators that demand unique, quality, consistent products. For more information on Front Range Biosciences, visit http://www.frontrangebio.com.

Media Contact MATTIO Communications [emailprotected]

SOURCE Front Range Biosciences

Excerpt from:
Front Range Biosciences Introduces A New Class of THCv Genetics That Will Boost Market Opportunities for New Consumer Experiences and Functional...

Neuroscience

Neuroscience Antibodies & Assays Market Statistics 2020, Technology Analysis Overview, Industry Insights and COVID-19 Pandemic Presenting Future…

February 4, 2021 medical

Neuroscience Antibodies & Assays Market research report delivers a comprehensive study on production capacity, consumption, import and export for all major regions across the world. Report provides is a professional inclusive study on the current state for the market. Analysis and discussion of important industry like market trends, size, share, growth estimates are mentioned in the report.

Neuroscience involves the study of nervous system, where the research is completely relies on assays and antibodies. These antibodies and assays are specific that helps to identify and examine reactions on the cellular, biochemical and molecular level. Antibody-based approaches are used for the localization, isolation and characterization of targeted proteins that majorly used in the cellular and molecular neuroscience. On the other hand, the use of assays provide an efficient, valuable solution for determination of critical targets that are involved in synaptic signaling, neural development and neurodegeneration.

Request For Exclusive Sample PDF of this Report @ https://www.theinsightpartners.com/sample/TIPBT00002234/?utm_source=10392_mccourier

Competitive Landscape Neuroscience Antibodies & Assays Market:

The global neuroscience antibodies & assays market is segmented on the basis of product, technology, application and end user. Based on product, the market is segmented as consumables and instruments. On the basis of technology, the global neuroscience antibodies & assays market is segmented into molecular diagnostics, clinical chemistry, immunoassays/immunochemistry and others. Based on application, the market is segmented as in vitro diagnostics, research and drug discovery. Based on end user, the market is segmented as hospitals & diagnostics centers, academic & research institutes and pharmaceutical & biotechnology companies.

The report specifically highlights the Neuroscience Antibodies & Assays market share, company profiles, regional outlook, product portfolio, a record of the recent developments, strategic analysis, key players in the market, sales, distribution chain, manufacturing, production, new market entrants as well as existing market players, advertising, brand value, popular products, demand and supply, and other important factors related to the market to help the new entrants understand the market scenario better.

To comprehend global Neuroscience Antibodies & Assays market dynamics in the world mainly, the worldwide market is analyzed across major global regions: North America (United States, Canada and Mexico), Europe (Germany, France, United Kingdom, Russia and Italy), Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia), South America (Brazil, Argentina), Middle East & Africa (Saudi Arabia, UAE, Egypt and South Africa)

Our Sample Report Accommodate a Brief Introduction of the research report, TOC, List of Tables and Figures, Competitive Landscape and Geographic Segmentation, Innovation and Future Developments Based on Research Methodology

Research Objective

To analyze and forecast the market size of global Neuroscience Antibodies & Assays market.

To classify and forecast global Neuroscience Antibodies & Assays market based on product, sources, application.

To identify drivers and challenges for global Neuroscience Antibodies & Assays market.

To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in global Neuroscience Antibodies & Assays market.

To conduct pricing analysis for global Neuroscience Antibodies & Assays market.

To identify and analyze the profile of leading players operating in global Neuroscience Antibodies & Assays market.

-To analyze global Neuroscience Antibodies & Assays status, future forecast, growth opportunity, key market and key players.

-To present the Neuroscience Antibodies & Assays development in various regions like United States, Europe and China.

-To strategically profile the key players and comprehensively analyze their development plan and strategies.

-Neuroscience Antibodies & Assays market report helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

Reasons to Buy:

Interested in Purchasing this Report? Click here @ https://www.theinsightpartners.com/buy/TIPBT00002234/?utm_source=10392_mccourier

Note: If you have any special requirements, please let us know and we will offer you the report as you want.

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defense.

Call: +1-646-491-9876

Email: sales@theinsightpartners.com

Read the original here:
Neuroscience Antibodies & Assays Market Statistics 2020, Technology Analysis Overview, Industry Insights and COVID-19 Pandemic Presenting Future...

Biochemistry

Bio-Based Itaconic Acid Market | Present Scenario, Key Vendors, Industry Share, and Growth Forecast up to 2027 | Thermo Fisher Scientific., Itaconix…

January 31, 2021 medical

The Bio-Based Itaconic Acid Marketreport mainly encompasses fundamental dynamics of the market which include drivers, restraints, opportunities and challenges faced by the industry.It provides valuable insights with an emphasis on global market including some of the major players.The report puts a light on the market structures, driving forces, scope, and competitive landscape for your business whichhelps ineffortless decision-making process.

The report displays the systematic investigation of current scenario of the market, which covers several market dynamics. The principal areas of market analysis such as market definition, competitive analysis,market segmentation, and research methodology are studied very vigilantly and precisely throughout the report.

Market Definition & Scope:

Bio-based itaconic acid market is expected to grow at a rate of 5.50% for the forecast period of 2020 to 2027. Data Bridge Market Research report on bio-based itaconic acid market provides analysis and insights regarding the various factors expected to be prevalent throughout the forecasted period while providing their impacts on the markets growth.The changing trend towards eco-friendly products due to growing awareness regarding green house emissions will help impact the bio-based itaconic acid market growth in the forecast period.

Competitors Analysis:CompetitorsProfiles Includes: Overview, Product & Services Offerings, Financials,New Developments and Innovation

The major players covered in the bio-based itaconic acid market report are Thermo Fisher Scientific., Itaconix Corporation, Qingdao Kehai Biochemistry Co., LTD., AEKYUNG PETROCHEMICAL Co., Ltd, Zhejiang Guoguang Biochemistry Co.,Ltd., Spectrum Ultimate Chem India Pvt. Ltd, Alpha Chemika, Haihang Industry Co., Ltd, Ronas Chemicals Ind. Co., Ltd., Hefei TNJ Chemical Industry Co.,Ltd., Alfa Aesar, Merck KGaA, Choice Organochem Llp., FUSO CHEMICAL CO., LTD., Henan Haofei Chemical Co.,Ltd., Chemical Manufacturing Corp and FUJIFILM Wako Pure Chemical Corporation, among other domestic and global players. Market share data is available for global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Download Free PDF Sample Report with Statistical info @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-bio-based-itaconic-acid-market

Bio-Based Itaconic Acid Market report covers the different market scenarios that have direct impact on the growth of the market. The report is structured with the meticulous efforts of an innovative, enthusiastic, knowledgeable and experienced team of analysts, researchers, industry experts, and forecasters. In the end, the report makes some important proposal of the new project of Bio-Based Itaconic Acid industry before evaluating its feasibility.

Report includes analysis on:

Key Market Development:

The report provides in-depth information about profitable showing markets and analyzes the markets for the global Bio-Based Itaconic Acid market. It provides full information about new product launches, current developments, and investments in the global market. The report delivers an complete evaluation of market shares, strategies, products, and manufacturing capabilities of the top players in the global market.

For Any Enquiry or Specific Requirement Speak to Our Analyst @https://www.databridgemarketresearch.com/speak-to-analyst/?dbmr=global-bio-based-itaconic-acid-market

This Bio-Based Itaconic Acid report provides Scope of the market where it identifies industry trends, determines brand awareness and influence, provides industry insights and offers competitive intelligence. Bio-Based Itaconic Acid Market report includes noteworthy information alongside future conjecture and point by point market scanning on a worldwide, regional and local level for the industry.

Key Pointers in Table of Content:

Chapter 1. Research Objective1.1 Objective,Definition & Scope1.2 Methodology1.2.1 Primary Research1.2.2 Secondary Research1.2.3 Market Forecast Estimation & Approach1.2.4 Assumptions & Assessments1.3 Insights and Growth Relevancy Mapping1.4 Data mining & efficiency

Chapter 2. Executive Summary2.1 Bio-Based Itaconic Acid Market Overview2.2 Interconnectivity & Related markets2.3 Bio-Based Itaconic Acid Market Business Segmentation2.4 Bio-Based Itaconic Acid Market Geographic Segmentation2.5 Competition Outlook2.6 Key Statistics

Chapter 3. Strategic Analysis3.1 Bio-Based Itaconic Acid Market Revenue Opportunities3.2 Cost Optimization3.3 Covid19 aftermath Analyst view

Chapter 4. Market Dynamics4.1 DROC4.1.1 Drivers4.1.2 Restraints4.1.3 Opportunities4.1.4 Challenges4.2 PEST Analysis4.2.1 Political4.2.2 Economic4.2.3 Social4.2.4 Technological4.3 Market Impacting Trends4.4 Porters 5-force Analysis

Chapter 5. Segmentation & Statistics5.1 Segmentation Overview5.2 Demand Forecast & Market SizingContinued..

Get Full Table of Contents with Charts, Figures & Tables @ https://www.databridgemarketresearch.com/toc/?dbmr=global-bio-based-itaconic-acid-market

About Us:

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delve into the markets across Asia, North America, South America, Africa to name few.Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Data Bridge Market Research

Tel: +18883872818

corporatesales@databridgemarketresearch.com

Human Behavior

Data Collected from IoT Devices Will Breed the Next New ‘Uber’ or ‘Netflix’, Predicts Eseye – insideBIGDATA

January 31, 2021 medical

What organizations can do with data is set to dramatically shift in 2021 and beyond, according to IoT connectivity specialist Eseye, as more IoT devices are deployed and the data they generate dwarfs that collected through traditional online channels. Eseye predicts that data mined from user interactions with things rather than digital services will create a wealth of rich data, bigger and more detailed than online data ever was, enabling new business models, the creation of new products and services and new levels of understanding of human behavior.

Services like Amazon, Facebook and Netflix capture a wealth of consumer usage and behavior data which is stored, analyzed, and used to digitize and reinvent shopping, social interactions, and entertainment as custom personalized, data-driven services. This has had an extraordinary effect on the creation of new personalized services and new disruptive business models. As radical a change as this was, now IoT data is set to power unprecedented levels of innovation over the coming years.

According to Eseye, this innovation will be seen not just in the next generation of classic IoT devices, which will become much more interactive and personalized to real time behavior, but also in the development of a new set of devices created through the fusion of multiple sensors, cellular connectivity to the cloud and advanced AI techniques. This combination will enable near real time predictions of what services should be dynamically configured into those devices to maximize revenue and collect even more data and deliver huge value.

IoT companies that see the potential, not just in the device but also in the data collected, will be the big winners, comments Nick Earle, CEO, Eseye. As we come out of the pandemic, organizations will be looking for new ways to innovate, and IoT data has the potential to disrupt business models and processes in practically every industry. Disruption, by its nature, comes from places we havent even dreamed of, but it can be radical. For example, the people who invented the internet could never have predicted the emergence of services such as Uber and Netflix. Likewise, we can only speculate around what IoT entrepreneurs will come up with once they have access to data from billions of devices capturing rich intelligence on every aspect of our lives and businesses. We predict it will be an even bigger wave of innovation than the first wave of IoT adoption.

One of Eseyes customers is already using rich data to predict diseases before they happen. A leading digital therapeutics provider manufactures and sells a next-generation clinical-grade wearable, which delivers actionable insights powered by machine learning, deep neural networks, and AI on real time disease trajectory. This helps clinicians predict and prevent serious medical events. For example, chronic diseases, like heart failure, can lead to billions of pounds of unnecessary hospitalizations and re-admissions. Therefore, the potential benefits across the healthcare sector if this model becomes widely adopted are enormous.

Another example is how IoT is helping vulnerable people remain independent through condition monitoring, whereby such devices use personal health data combined with behavioral patterns, and analytics predict when changes in care regimes might be required. These are just two examples of millions of potential applications.

In 2020 the pandemic has accelerated many of the IoT trends we predicted last year. Thats because an economic slowdown, like we are experiencing, puts enormous pressure on enterprises to reduce costs and increase customer delivered value. IoT does both of these things, and so the pressure for adoption is growing. This sudden need for new technological approaches has happened at a time when IoT is reaching a level of cost and maturity that allows for mainstream adoption. This will increase the ability to collect rich data from these next generation IoT devices, delivering unimaginable insights to power innovation in years to come, adds Earle.

This is just one of 10 IoT predictions that Eseye is forecasting for 2021 and beyond. Others include how IoT can deliver real time visibility into the food supply chain with technology advances such as printing IoT circuits, batteries, and cellular connectivity onto flexible labels. Its exploring how IoT as it becomes more integrated into consumer and industrial products can provide brands with a direct line to customers, collapsing supply chains to bring original equipment manufacturers closer to consumers.

Furthermore, Eseye is also analyzing how mobile network operators (MNOs) are adapting to compete globally and why a federation approach creates a more viable economic model for MNOs to deliver IoT, as well as the emergence of virtual MNOs. Eseye announced its global alliance of MNOs, The AnyNet Federation, in 2019 and over the last year the AnyNet Federation has grown to 12 MNO members, a number which Eseye expects to further grow in 2021.

Join us on Twitter:@InsideBigData1 https://twitter.com/InsideBigData1

More here:
Data Collected from IoT Devices Will Breed the Next New 'Uber' or 'Netflix', Predicts Eseye - insideBIGDATA

Neuroscience

$25 million gift to Brown will fuel innovation in brain science – Brown University

January 27, 2021 medical

PROVIDENCE, R.I. [Brown University] A new $25 million gift to Brown University will fuel scientific discovery and help innovative new ideas in brain science get off the ground.

The generous gift from a donor who wishes to remain anonymous will support research in computational brain science, enabling Brown to attract and retain world-class teachers and scholars, and it will endow an innovation awards program at the Universitys Robert J. and Nancy D. Carney Institute for Brain Science to provide seed funding for new high-impact research in computation and other areas of brain science.

This transformational gift recognizes the momentum that continues to build at Brown University, where our talented faculty are leading scientific discovery including in the rapidly emerging specialty of computational brain science, said Diane Lipscombe, director of the Carney Institute and a professor of neuroscience. This gift will allow us to sustain a culture of innovation, which has led to an impressive number of discoveries and returned countless new grants to Brown that forge new areas of research.

Professor of Neuroscience David Berson prepares a microscope stage for fluorescence imaging and recording of electrical activity. Berson received an innovation award in 2018 for a project to develop methods for faster, more accurate and more versatile segmentation software for electron-microscopic analysis.

With more than 180 affiliated faculty members in 20 units and eight affiliated graduate programs, the Carney Institute is pursuing research that has real-life, human applications, Lipscombe said. Core areas of research include work on innovative advances in computational brain science to investigate cognition, behavior and mood disorders; novel technologies to interface with the brain to understand brain circuits and restore lost functions; and research into the mechanisms of cell death to identify therapies for neurodegeneration, such as in amyotrophic lateral sclerosis (ALS) and Parkinsons and Alzheimers diseases.

This new $25 million gift is part of the Universitys $3-billion BrownTogether campaign, which has raised $2.74 billion to date. It also builds upon significant philanthropic investment in Browns cutting-edge work in brain science of the total contributed by donors to date, more than $187 million has been raised to support research and education in brain science, including a $100 million gift that named the institute in 2018. The gifts support a core research priority in Browns Building on Distinction strategic plan: understanding the human brain.

In 2014, the Carney Institute launched an innovation awards program to support early-stage research projects that are too new to attract external funding but have great potential to advance science and benefit society. The new gift will endow a similar innovation awards program, ensuring that the Carney Institute will be able to sustainably invest in innovation for years to come.

Ashley Webb, an assistant professor of molecular biology, cell biology and biochemistry at Brown, received an innovation award in 2019 to establish a new system to study how neurons age. She is developing a cell reprogramming platform, called direct reprogramming, to study aging in the hypothalamus brain region. The hypothalamus controls critical processes, such as sleep, temperature regulation, eating and metabolism, which can become dysregulated with aging. With direct reprogramming, Webb is able to convert a skin cell, for example, into a brain cell that maintains the hallmarks of aging.

From studying genes and circuits, to healthy behavior and psychiatric disorders, Carney Institute faculty produce insights and tools to see, map, understand and fix problems in the nervous system.Aging is the greatest risk factor for a number of diseases, including neurodegenerative diseases such as Alzheimers, Webb said. If we understand whats going wrong during aging, this will give us important insight into the mechanisms of disease. But right now, we dont have very good systems for studying these diseases in the context of aging. This is the problem we are working to solve.

Starting from mouse skin cells, Webbs group generated rare hypothalamic brain cells, called POMC neurons, that are important for metabolic health and weight control. Normally, these cells trigger satiety (the feeling of being full), but they lose the ability to do so as they age.

Webb is now applying the same approach to create POMC neurons from human cells, which for the first time will allow researchers to generate rare types of human neurons that are physiologically aged.

If we take cells from aged individuals, the neurons we generate actually retain damage associated with aging, Webb said. This allows us to compare young and aged neurons, and understand why the old neurons dont function as well. We believe this platform will give us important insight into why metabolism is altered with age and in many diseases.

The Innovation Awards Program, Webb said, gave her group the freedom to take on a bold, early-stage idea. Her team hopes to use the direct reprogramming approach to generate neurons from individuals with brain diseases and disorders, such as Alzheimers.

See the original post here:
$25 million gift to Brown will fuel innovation in brain science - Brown University

Genetics

Cure Genetics Collaborates with Boehringer Ingelheim to Develop Novel AAV Vectors Enabling the Next-generation Liver-targeted Gene Therapy -…

January 20, 2021 medical

SUZHOU, China, Jan. 18, 2021 /PRNewswire/ -- Cure Genetics announced a collaboration with Boehringer Ingelheim to develop novel Adeno-Associated Virus (AAV) vectorsleveraging Cure Genetics' proprietary VELPTM platform to develop next-generation gene therapies. This new collaboration combines Boehringer Ingelheim's experience in disease biology and gene therapy development with Cure Genetics' AAV expertise in library construction and highly efficient in vivo AAV screening. The aim is to provide potential new AAV serotypes for patients.

The clinical applications of existing AAV serotypes are limited by some of their features, such as low transduction efficiency, low tissue specificity and immunogenicity. Therefore, finding new AAV serotypes to overcome these challenges becomes critical for the majority, if not all, AAV-based gene therapies.

Comparing to other traditional vector engineering technologies, Cure Genetics' proprietary VELPTM platform encompasses key methodical innovations, including a comprehensive strategy of engineering a plasmid library with high complexity and an effective ratio. the optimized AAV production protocol ensures high genome-capsid correspondence and world-class production capacity, and the most physiologically relevant models for vector selection and validation. It enables a significantly shorter process to find the "right" AAV vectors with almost all possibility effectively covered.

Boehringer Ingelheim aspires to develop the next generation of medical breakthroughs and gene therapy is one of the focuses under exploration by the team of Research Beyond Borders. The advanced VELPTM technology platform may provide effective solutions in increasing the efficiency of novel AAV screening and help further expand our efforts in the area of gene therapy development.

"This is the very first time that a global pharmaceutical group is collaborating with a Chinese biotech in the cutting-edge field of AAV vector engineering. We appreciate the recognition of Boehringer Ingelheim's recognition of our VELPTM platform. Novel AAV vectors enlarging the therapeutic window is key to unfolding the potential of gene therapy, which is also Cure Genetics' innovative focus . We believe, together with visionary partners like Boehringer Ingelheim, the quality of life for more patients in need can be improved by next-generation gene therapy." stated Dr. Qiushi Li, Cure Genetics' Chief Operating Officer.

The collaboration with Cure Genetics was initiated by Boehringer Ingelheim China External Innovation Hub. It consists of three business units: Research Beyond Borders, Business Development and Licensing, and Venture Fund. The hub is committed to becoming the preferred partner of China's biopharmaceutical industry and bringing more Chinese innovative partnership projects to enrich Boehringer Ingelheim's global R&D pipeline, thereby ultimately benefiting more patients. So far, Boehringer Ingelheim China External Innovation Hub has established various partnerships with reputable research institutions and biotech companies in China.

About Cure Genetics

Cure Genetics is a biotech company founded in 2016, committed to expanding the frontier of gene therapy via its innovative technology of gene editing and gene delivery. With the world-leading AAV manufacturing capability, Cure Genetics' proprietary VELPTM platform enables a fast yet systematic design, selection and optimization of AAV vectors with special features and significantly better performance of in vivo gene delivery, which will empower AAV-based gene therapy to be applied in a much broader range of disease treatments.

SOURCE Boehringer Ingelheim; Cure Genetics

Follow this link:
Cure Genetics Collaborates with Boehringer Ingelheim to Develop Novel AAV Vectors Enabling the Next-generation Liver-targeted Gene Therapy -...

Cell Biology

Aviceda Therapeutics Announces Formation of Executive Team – Business Wire

January 13, 2021 medical

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aviceda Therapeutics, a late-stage, pre-clinical biotech company focused on developing the next generation of immuno-modulators by harnessing the power of glycobiology to manipulate the innate immune system and chronic, non-resolving inflammation, is announcing the composition of the Executive Team that will guide the company through ongoing development of breakthrough, first-in-class therapeutics and continued growth opportunities as a business entity.

Serving in key leadership roles on Avicedas Executive Leadership Team will be:

Aviceda is extremely proud of the world-class team of internationally renowned experts we have assembled to guide the company in the next phases of growth. In addition to offering keen scientific insight into product development, each member of the Executive Team also brings with them previous experience in key leadership positions in the pharmaceutical industry. Being able to tap into this knowledge base will undoubtedly pay huge dividends as Aviceda pursues an aggressive but realistic growth and product development strategy, said Dr. Genead, who is a Co-Founder of Aviceda.

A serial life-sciences entrepreneur, senior innovative biopharma executive, inventor, and consultant to many ophthalmic biotechnology companies and healthcare venture firms, Dr. Genead is widely regarded as a global executive and senior leader with 20-plus years experience in pharmaceutical drug and business development with execution from discovery to late development and commercial phases. He has played key roles in executing global approvals and launches and driving sales growth in country, regional and global development positions together with direct reporting teams.

Dr. Genead previously served as Chief Medical Officer and Executive Vice-President for GenSight Biologics where he led the clinical team to multiple phase I-III trials leveraging a disruptive ocular gene therapy and optogenetics platforms in patients with retinal degenerative diseases. Prior to GenSight, Dr. Genead was Biogens Head of Ophthalmology and Retina Gene Therapy. Dr. Genead has also held leadership positions with Allegro Ophthalmics, where he led the global clinical development teams for the Risuteganib (anti-integrin) platform, and Allergan, where he was Global Medical Director and Clinical Team Lead for Retina Therapeutic area. Dr. Genead is a Co-founder of several start-ups, has been instrumental in the raising of over $500M in venture and institutional capital for numerous life sciences biotech companies and is currently a board member of several ophthalmic organizations and scientific advisory boards. Dr. Genead is a board-certified ophthalmologist/retina specialist by training, having completed a vitreoretinal fellowship at the Department of Ophthalmology and Visual Sciences of the University of Illinois in Chicago and Medical College of Wisconsin. He has served as a principal Investigator with a proven record of success in developing and launching global blockbuster therapeutics. He was the primary and key author for numerous peer-reviewed manuscripts in high impact factor scientific journals (more than 100 manuscripts and presentations) focusing on clinical research and novel therapeutics.

Dr. Callanan is a board-certified ophthalmologist, a clinical Professor at the University of Texas Southwestern Medical School in Dallas, Texas and surgeon with Texas Retina Associates, specializing in vitreoretinal diseases including uveitis, diabetic retinopathy and age-related macular degeneration.

Dr. Callanan earned his medical degree at the University of Iowa College of Medicine and completed his ophthalmology residency at Parkland Memorial Hospital, University of Texas Southwestern Medical Center. He received a National Research Service Award from the National Institutes of Health for the study of Ocular Immunology with Dr. Jerry Niederkorn. He was a Heed Ophthalmic Foundation Fellow at the prestigious Bascom Palmer Eye Institute in Miami, Florida. He completed fellowships in medical retina with legendary Dr. J. Donald M. Gass and vitreoretinal surgery with the Bascom Palmer faculty. Dr. Callanan also received additional training in uveitis with Dr. Robert Nussenblatt at the National Eye Institute in Bethesda, over 60 peer reviewed articles and several book chapters, Dr. Callanan is widely regarded as a respected leader in his field. Throughout his career he has actively conducted clinical research and has played an instrumental role in several ophthalmic drug approvals. In addition to his clinical and academic responsibilities, Dr. Callanan also serves on the board of directors of the Retina Foundation of the Southwest and is a member of numerous professional and honorary societies, including the American Academy of Ophthalmology, The Association for Research in Vision and Ophthalmology, The Macula Society, The American Uveitis Society, and the American Society of Retina Specialists, among others.

I am thrilled to join Aviceda at an exciting time for the company and its portfolio of pipeline candidates. Glyco-immune therapeutics offers the prospect of a truly transformational approach to treating a variety of underserved immune mediated inflammatory conditions that do not have adequate therapeutic options. While our immediate focus will be on ophthalmic conditions, there is tremendous potential to improve treatment options for a wide assortment of conditions affecting the innate immune system, said Dr. Callanan.

Dr. Kunimoto, who is a co-Founder of Aviceda, holds a medical degree with honors from Harvard Medical School and a law degree with honors from Oxford University, which he attended on a Rhodes Scholarship. He was a medicine intern at Massachusetts General Hospital and completed his residency at Wills Eye Hospital in Philadelphia, where he served as co-chief resident. Dr. Kunimoto was recognized as a Heed and Michaels Fellow. He worked as a consultant with the management consultancy, McKinsey & Co. Dr. Kunimoto has authored numerous peer-reviewed publications, two major ophthalmology textbooks, and has been invited to speak at ophthalmology conferences, both nationally and internationally. Dr. Kunimoto has been very active in the clinical research of retinal diseases, acting as Investigator or Principal Investigator in over 150 global clinical trials. A recipient of numerous honors for academic and research achievements, Dr. Kunimoto served as Managing Partner of Retinal Consultants of Arizona, where he lead efforts to grow the practice to 35 locations, develop a nutraceutical franchise, and establish an Aviation Department for transportation and patient coverage at outlying satellite offices. He also served as Manager of the Retina Research Institute. Dr. Kunimoto is a founding member and served as Founding President of the Vit-Buckle Society, served as Chair of the Medical Student Governing Council in the Massachusetts Medical Society, and as a member on the Council on Constitution and Bylaws of the American Medical Association. Outside of medicine, Dr. Kunimoto serves on the Board of Directors of the Association of American Rhodes Scholars.

Prior to graduating with a medical degree from the University of Massachusetts, Dr. Tolentino performed research on retinal degeneration at the Schepens Eye Research Institute and the Berman Gund Lab (both at Harvard Medical School), as well as the National Eye Institute. After Medical School, Dr. Tolentino did a post-doctoral angiogenesis research fellowship in the lab of Dr. Judah Folkman, where he helped develop a cancer/xenograft model to screen for angiogenic inhibitors, work that demonstrated the role of Vascular Endothelial Growth Factor (VEGF) in macular degeneration, diabetic retinopathy and vein occlusion. During this time he purified Bevacizumab (Avastin), a drug designed for oncologic applications, and demonstrated intravitreal application could inhibit ocular neovascularization, a discovery that led to the eventual development of anti-VEGF therapeutics for retinal disease. After finishing his Ophthalmology Residency, Dr. Tolentino joined the retina and molecular ophthalmology faculty at the University of Pennsylvania, where he ran a lab funded by the National Institutes of Health working on gene, cell and RNAi therapy. Among his many accomplishments is the invention of a new class of gene silencing molecules called small interfering RNA (siRNA) against anti-angiogenic targets. He has 3 issued patents on the composition and methods of use of these molecules in vertebrate organisms for treating neovascular diseases. The discovery of siRNA and its mechanisms in invertebrate worms resulted in the Nobel prize in Medicine for Craig Mello and Andrew Fire in 2006. Dr. Tolentino co-founded and served as the interim CEO/CSO for Acuity Pharmaceuticals, where he was able to herald the first siRNA therapeutic into human clinical trials. Acuity eventually merged with Exegenic Inc to form OPKO health (NYSE: OPK), a publicly traded biopharmaceutical company. Over the course of his career, Dr. Tolentino has been very active in the clinical research of retinal diseases, acting as principal investigator in over 150 clinical trials that led to multiple global approvals for retinal therapeutics. He has authored over 100 publications and delivered over 200 international lectures. He has served as a consultant/scientific advisor for numerous pharma/biotech companies.

Prof. Scott, Aviceda Scientific Co-Founder, is Director of the Patrick G Johnston Centre for Cancer Research and Cell Biology at Queens University Belfast. He is internationally renowned for his work in development of novel approaches in the field of antibody and nanomedicine-based therapies for the treatment of cancer and other conditions. Prof. Scott has a background in both the pharmaceutical industry and academia and was a founding scientist of Fusion Antibodies Plc. Research in his laboratory is funded by agencies such as Medical Research Council, UK charities and various industrial sources. He also held a Royal Society Industrial Fellowship with GSK from 2012 to 2015 and won the Vice Chancellors Prize for Innovation in 2015 with his groups work on developing a novel Siglec targeting nanomedicine for the treatment of sepsis and other inflammatory conditions.

About Aviceda Therapeutics

Founded in 2018 and based in Cambridge, Massachusetts, Aviceda Therapeutics is a late-stage, pre-clinical biotechnology company with a mission to develop the next generation of glyco-immune therapeutics (GITs) utilizing a proprietary technology platform to modulate the innate immune system and chronic, non-resolving inflammation. Aviceda has assembled a world-class, cross-disciplinary team of recognized scientists, clinicians and drug developers to tackle devastating ocular and systemic degenerative, fibrotic, oncologic and immuno-inflammatory diseases. At Aviceda, we exploit a unique family of receptors expressed on all innate immune cells and their associated glycobiological interactions to develop transformative medicines. Combining the power of our biology with our innovative cell-based high-throughput screening platform and proprietary nanoparticle technology, we can modulate the innate immune response specifically and profoundly. Aviceda is developing a pipeline of GITs that are delivered via biodegradable nanoparticles and which safely and effectively target numerous immune-inflammatory conditions. Avicedas lead ophthalmic optimized nanoparticle, as an intravitreal formulation, AVD-104, is being developed to target various immune system responses that contribute to the pathology associated with age-related macular degeneration (AMD).

See more here:
Aviceda Therapeutics Announces Formation of Executive Team - Business Wire

Cell Biology

LyGenesis Receives FDA Clearance to Begin Phase 2a Trial of its Cell Therapy for Patients with End Stage Liver Disease, and also Closes $11 Million…

December 31, 2020 medical

PITTSBURGH, Dec. 30, 2020 /PRNewswire/ --LyGenesis, Inc., a biotechnology company developing cell therapies that enable organ regeneration, announced today that the U.S Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application.Under the IND, LyGenesis will be conducting a Phase 2a study on the safety, tolerability, and efficacy of its first-in-class novel cell therapy for patients with end stage liver disease (ESLD).

In addition, LyGenesis just completed over $11 million in private financing of convertible notes led by Juvenescence, Ltd. and Longevity Vision Fund. Proceeds will be used to fund LyGenesis's Phase 2a clinical trial with a first patient in targeted for early 2021, as well as to push forward on their other cell therapies using lymph nodes as bioreactors to regrow functioning organs, including pancreas, kidney, and thymus regeneration.

"The FDA clearance for our IND and the start of our Phase 2a study in patients with ESLD is a testimony to our robust preclinical research program, the unmet need in advanced liver disease, and our novel approach to organ regeneration. Moreover, the lack of genetic manipulation, ease of administration, and low cost of goods for our cell therapy forms the foundation for a promising and scalable first commercial product," said Michael Hufford, PhD, Co-Founder and CEO of LyGenesis.

"LyGenesis's progress has been simply extraordinary. They have recently published 4 peer-reviewed papers on their regenerative medicine technology, filed and received clearance for their first IND, identified a primary site for their Phase 2a clinical trial, and now have closed a round of financing to ensure they have the cash to run their trial and also progress additional cell therapies toward the clinic," said Jim Mellon, Co-Founder of Juvenescence, and Chair of LyGenesis's Board of Directors. Sergey Young, founder of Longevity Vision Fund, said "We are excited to support LyGenesis in its vision to tackle some of the most challenging unmet medical needs of our time with a unique organ regeneration technology. By enabling one donated organ to act as a source of therapies for dozens of patients, LyGenesis is on the cusp of disrupting the supply-demand calculus of organ donation, and this regulatory clearance from the FDA is a definitive milestone in their evolution."

About LyGenesis, Inc.LyGenesis is a biotechnology company with an organ regeneration technology platform enabling a patient's lymph nodes to be used as bioreactors to regrow functioning ectopic organs. LyGenesis's lead allogeneic cell therapy program is focused on liver regeneration for patients with end stage liver disease. Its drug development pipeline includes thymus, pancreas, and kidney regeneration. Privately held, LyGenesis is headquartered in Pittsburgh, Pennsylvania. To learn more, please visit lygenesis.com.

About Juvenescence, Ltd.Juvenescence Ltd. is a life sciences company developing therapies to modify aging increasing human health span and longevity. It was founded byJim Mellon,Dr. Gregory BaileyandDr. Declan Doogan. The Juvenescence team are highly experienced drug developers, entrepreneurs and investors with a significant history of success in the pharmaceutical and consumer health sectors. Juvenescence will create, partner with or invest in new companies with longevity-related therapeutics, by in-licensing compounds from academia and industry, or forming joint ventures to develop therapeutics for longevity. Juvenescence believes that recent advances in science have greatly improved our understanding of the biology of aging and seeks to develop therapeutics with the possibility of slowing, halting or potentially reversing elements of aging. To learn more, please visit juvlabs.com.

About Longevity Vision FundLongevity Vision Fund is a venture capital fund that invests in technologies with the potential to disrupt life sciences to help people live longer and healthier lives. The fund is focused on early diagnostics, AI in healthcare, and advanced therapeutic platforms targeting aging and age-related diseases. It was founded by Sergey Young, a venture capital investor with a mission to make longevity more accessible and affordable. Sergey is also an Innovation Board member at XPRIZE Foundation and a development sponsor of Age Reversal XPRIZE. To learn more, please visit lvf.vc.

Contact InformationMichael Hufford(858) 603-2514262126@email4pr.com

View original content:http://www.prnewswire.com/news-releases/lygenesis-receives-fda-clearance-to-begin-phase-2a-trial-of-its-cell-therapy-for-patients-with-end-stage-liver-disease-and-also-closes-11-million-convertible-debt-financing-301199042.html

SOURCE LyGenesis, Inc.

More here:
LyGenesis Receives FDA Clearance to Begin Phase 2a Trial of its Cell Therapy for Patients with End Stage Liver Disease, and also Closes $11 Million...